University of Gothenburg
  2. About
  3. Find staff
  4. Lennart Jacobsson

Lennart Jacobsson

Professor Emeritus

Department of Rheumatology and Inflammation Research
Telephone
+46 31-343 98 23
Mail
lennart.jacobsson@gu.se
Visiting address
Guldhedsgatan 10
41390 Göteborg
Postal address
Box 480
40530 Göteborg

About Lennart Jacobsson

Lennart Jacobsson (born 1954) has a long experience in clinical and epidemiological research of rheumatoid arthritis, pain syndromes, Sjögren´s syndrome, spondyloarthritis and gout.

His group has published several key original findings, such as the protective effect of TNF-inhibitors on cardiovascular events in rheumatoid arthritis and mechanism behind lymphoma development in Sjögren´s syndrome.

Currently his group are exploring the epidemiology of various forms of spondyloarthritis and gout, using both unique source of national Swedish registers and translational research of clinical cohorts. Recently, they have through epidemiological studies demonstrated the differential effect of different TNF-inhibitors on the risk of uveitis in AS and a possible deleterious effect of low serum uric acid levels on the risk of Alzheimers disease.

For his scientific work he was awarded the Nanna Svartz price in 2010 and the Pfizer rheumatology prize in 2014.


Key Publications

  • Lie, E, Lindstöm U, Zverkova-Sandström T, Olsen IC, Forsblad-d’Elia H, Askling J, Kristensen LE, Jacobsson LTH. The Effect of TNF Inhibitor Treatment on Occurrence of Anterior Uveitis in Ankylosing Spondylitis: Results from the Swedish Biologics Register. Ann Rheum Dis. 2017 Mar 2. pii: annrheumdis-2016-210931. doi: 10.1136/annrheumdis-2016-210931.
  • Dehlin M, Drivelegka P,, Sigurdardottir V, Svärd A, Jacobsson LTH. Incidence and prevalence of gout in VGR, Sweden. Arthritis Research and Therapy. 2016 Jul 13;18:164. doi: 10.1186/s13075-016-1062-6
  • Lindström U, Exarchou S, Lie E,Dehlin M, Forsblad-d'Elia H, Askling J, Jacobsson LTH. Childhood infections and later development of ankylosing spondylitis. A national case-control study. Arthritis Res Ther. 2016 Oct 22;18(1):240.
  • Jacobsson LT, Turesson C, Nilsson JA, Petersson I, Lindqvist E, Saxne T, Geborek P. Treatment with TNF-blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:670-675
  • Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LTH. Lymphoma and other malignancies in primary Sjögren´s syndrome. A cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006 Jun;65(6):796-803
  • Jacobsson LTH, Turesson C, Gülfe A, Crnkic M, Petersson IF, Saxne T, Geborek P. Treatment with TNF-blockers is associated with a lower incidence of first cardiovascular vents in patients with rheumatoid arthritis. J Rheumatol. 2005; 32: 1213 – 8.
  • Geborek P, Bladström A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LTH. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005; 64: 699 - 703.
  • Jacobsson LTH, Jacobsson ME, Askling J, Knowler WC. Perinatal characteristics and risk of rheumatoid arthritis a population-based case-control study. BMJ 2003; 326: 1068–9.
  • Bergman S, Herrström P, Högström K, Petersson IF, Svensson B, Jacobsson LT. Chronic widespread pain, prevalence rates and sociodemographic associations in a Swedish population study. J Rheumatol 2001; 20: 1369-1377.
  • L Jacobsson, BU Hansen, R Manthorpe, K Hardgrave, J Harley. Association of dry eyes and dry mouth with anti Ro/SS A and anti-La/SS B autoantibodies in normal adults. Arthritis Rheum 1992;35:1492-1501.
  • L Jacobsson, WC Knowler, RL Hanson, S Pillemer, DJ Pettitt, DR McCance, MA Charles, RG Nelson, PH Bennett. Rheumatoid arthritis and mortality. A longitudinal study in the Pima Indians. Arthritis Rheum. 1993;36:1045-1053.
  • L Jacobsson, F Lindgärde, R Manthorpe, K Ohlsen. Effect of education, occupation and some life style factors on common rheumatic complaints in a Swedish group aged 50-70 years. Ann Rheum Dis. 1992;52:835-843.